Abstract
The Tocilizumab in Patients with Severe COVID-19 Pneumonia (TESEO) study by Giovanni Guaraldi and colleagues1 provides vital information regarding the benefits of tocilizumab in severe pneumonia due to COVID-19. However, certain aspects of the study warrant deliberation in greater detail.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
